Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Hosted on MSN47m
FDA approves first non-addictive pain medication
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
FDA approves new type of nonopioid painkiller for acute pain
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.
Brand-new painkiller approved by US health agency
Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain and reduce the effects of the ...
kffhealthnews33m
From KFF Health News - Latest Stories:
Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...